Product Description
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pluri
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hip Fracture|Other
Phase 2: Muscle Cancer|Severe Acute Respiratory Syndrome|COVID-19|Bone Cancer|Peripheral Arterial Disease|Acute Respiratory Distress Syndrome|Pelvic Cancer|Pneumonia|Intermittent Claudication|Other|Osteoarthritis
Phase 1: Peripheral Vascular Diseases|Peripheral Arterial Disease|Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03746899 |
PLX-CLI-06 | N/A |
Available |
Other |
None |
2019-03-22 |
Treatments |
|
NCT03886506 |
PLX-CLI-05 | N/A |
No longer available |
Other |
None |
2024-09-20 |
Treatments|Trial Status |
|
NCT01795950 |
PLX-PH-101 | P1 |
Terminated |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2015-12-01 |
2019-03-19 |
||
NCT00919958 |
PLX-PAD 1202-1 | P1 |
Completed |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2012-06-01 |
2019-03-18 |
Treatments |
|
NCT00951210 |
NCT00951210 | P1 |
Completed |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2011-01-01 |
2019-03-18 |
Treatments |
|
2023-504212-15-00 |
2023-504212-15-00 | P2 |
Withdrawn |
Osteoarthritis |
2028-10-31 |
2025-05-02 |
Treatments |
|
2020-001857-31 |
2020-001857-31 | P2 |
Completed |
Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome|COVID-19|Pneumonia |
2022-06-15 |
2022-03-13 |
Treatments |
|
NCT04614025 |
PLX-COV-03 | P2 |
Terminated |
COVID-19|Acute Respiratory Distress Syndrome |
2021-08-04 |
2023-10-12 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04389450 |
PLX-COV-01 | P2 |
Terminated |
COVID-19|Acute Respiratory Distress Syndrome |
2021-05-17 |
2023-10-11 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01679990 |
PLX 1204-01 | P2 |
Completed |
Intermittent Claudication|Peripheral Arterial Disease |
2018-03-29 |
2019-03-19 |
||
2011-004091-12 |
PLX-PAD 1204-01 | P2 |
Completed |
Intermittent Claudication |
2014-11-23 |
2022-03-13 |
Treatments |
|
2011-003934-16 |
PLX-PAD 1301-01 | P2 |
Active, not recruiting |
Other |
2014-08-27 |
2022-03-13 |
Treatments |
|
NCT01525667 |
PLX-PAD 1301-01 | P2 |
Completed |
Bone Cancer|Pelvic Cancer|Muscle Cancer |
2013-12-01 |
2019-03-19 |
Treatments |
|
2017-005165-49 |
2017-005165-49 | P3 |
Terminated |
Hip Fracture |
2022-08-02 |
2022-03-13 |
Treatments |
|
NCT03451916 |
PLX-HF-01 | P3 |
Completed |
Hip Fracture |
2022-04-29 |
2023-09-29 |
Primary Endpoints|Study Completion Date|Trial Status |
|
NCT03006770 |
PLX-CLI-03 | P3 |
Completed |
Other |
2021-03-03 |
2024-08-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2015-005532-18 |
2015-005532-18 | P3 |
Terminated |
Unknown |
2020-12-14 |
2025-07-03 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/10/2024 |
News Article |
IsomAb Announces the Expansion of its Clinical Advisory Board |
|
07/10/2024 |
News Article |
IsomAb Announces the Expansion of its Clinical Advisory Board |
|
03/28/2024 |
News Article |
Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences |
|
12/21/2023 |
News Article |
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction |